Tyvyt

(sintilimab)

Phase 3Monoclonal antibody

Sintilimab is used to treat certain types of cancer, particularly non-small cell lung cancer and other solid tumors, by helping the immune system recognize and attack cancer cells.[1] Tyvyt is currently being investigated across 76 indications[3], with its most advanced program in Phase 3.[1]

Tyvyt is one of 1163 small molecule programs targeting Pancreatic Carcinoma. It is currently in Phase 3.

Indications

294

Total Trials

Active Trials

1,162

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CarcinomaActive, not recruiting

Pancreatic NeoplasmActive, not recruiting

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Colorectal CarcinomaActive, not recruiting

MetastasisActive, not recruiting

Esophageal Squamous Cell CarcinomaActive, not recruiting

Clear Cell Renal CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Salivary Gland CancerActive, not recruiting

Undifferentiated Pleomorphic SarcomaActive, not recruiting

Pancreatic CarcinomaPhase 2

Active, not recruiting

Pancreatic NeoplasmPhase 2

Active, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Active, not recruiting

Colorectal CarcinomaPhase 3

Active, not recruiting

MetastasisPhase 2

Active, not recruiting

Esophageal Squamous Cell CarcinomaPhase 3

Active, not recruiting

Clear Cell Renal CarcinomaPhase 2

Active, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Salivary Gland CancerPhase 2

Active, not recruiting

Undifferentiated Pleomorphic SarcomaPhase 2

Active, not recruiting

Showing 10 of 76 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

1 2

Halaven

Eisai

Preclinical

38 3

Tecentriq

Roche

Preclinical

36 4

Trodelvy

Gilead

Preclinical

37 5

Tykerb

GSK

Preclinical

80 6

Adriamycin

GGynecologic Oncology Group

Preclinical

87 7

Avastin

BBio-Thera Solutions

Preclinical

153 8

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 9

Prolia

Amgen

Preclinical

14 10

Gemzar

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Esophageal Cancer

NCT06403878

Phase 1/2Active, not recruiting

Advanced Solid Tumors

NCT06220318

Phase 2Not yet recruiting

Breast Cancer

NCT06308939

Phase 2Recruiting

Colorectal Cancer

NCT05057052

Q4 2026

Phase 2Recruiting

Hepatocellular Carcinoma

NCT06558227

Phase 2Active, not recruiting

Locally-Advanced Rectal Cancer

NCT04304209

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma22 trials

TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07487662·90 enrolled

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Not yet recruiting·FFudan University··NCT07147101·150 enrolled

Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma

Unknown status·FFudan University·Phase 2·NCT06285019·65 enrolled

Show 19 more trials

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

Not yet recruiting·TTongji Hospital·Phase 3·NCT06089382·104 enrolled

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2/3·NCT05976568·668 enrolled

TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma

Completed·FFudan University·Phase 2·NCT04297280·25 enrolled

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Completed·SSun Yat-sen University··NCT04627012·600 enrolled

Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 2·NCT06558227·90 enrolled

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Recruiting·SSun Yat-sen University··NCT06323382·240 enrolled

Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05166772·30 enrolled

HAIC Combined with Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

Recruiting·FFudan University·Phase 2·NCT06860490·164 enrolled

Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

Unknown status·—·Phase 1·NCT05225116·20 enrolled

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

Unknown status· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 2/3·NCT03794440·595 enrolled

Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma

Recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT06618664·590 enrolled

A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma

Unknown status·SShanghai Zhongshan Hospital·Phase 1·NCT05363722·80 enrolled

Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma

Unknown status·BBaocai Xing·Phase 2·NCT04042805·36 enrolled

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

Not yet recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT07179900·60 enrolled

Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01)

Unknown status·MMian XI·Phase 2/3·NCT04167293·116 enrolled

HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

Completed·SSun Yat-sen University·N/A·NCT04618367·30 enrolled

TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)

Completed·FFudan University·Phase 2·NCT04954794·29 enrolled

HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma

Unknown status·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT05621499·60 enrolled

Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT05971199·27 enrolled

Gastric Cancer15 trials

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04267549·47 enrolled

Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer

Not yet recruiting·RRuijin Hospital·Phase 2·NCT06697366·27 enrolled

Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer

Unknown status·PPeking University·Phase 1/2·NCT04202601·80 enrolled

Show 12 more trials

A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07263386·460 enrolled

A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06555471·40 enrolled

Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer

Not yet recruiting·Zzhoujing·Phase 2·NCT07018063·35 enrolled

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05627414·30 enrolled

A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06564298·39 enrolled

Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens

Unknown status·FFujian Cancer Hospital·Phase 2·NCT04089657·40 enrolled

Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis

Unknown status·RRuijin Hospital·Phase 2/3·NCT05002686·60 enrolled

Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT03745170·650 enrolled

Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer

Terminated·FFudan University·Phase 2·NCT05161572·6 enrolled

Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04982939·210 enrolled

Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer

Unknown status·TTang-Du Hospital·Phase 2·NCT06123455·60 enrolled

Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer

Unknown status·RRenJi Hospital·Phase 2·NCT05795296·30 enrolled

Non-Small Cell Lung Cancer11 trials

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

Terminated· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT05088967·6 enrolled

A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer

Active, not recruiting·TTJ Biopharma Co., Ltd.·Phase 2·NCT07005336·150 enrolled

Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer

Unknown status·TTianjin Medical University Second Hospital·Phase 2·NCT04486287·44 enrolled

Show 8 more trials

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

Not yet recruiting·PPeking Union Medical College Hospital·Phase 2·NCT05306847·93 enrolled

Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Recruiting· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT05504278·144 enrolled

Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer

Recruiting·SSecond Xiangya Hospital of Central South University·Phase 1·NCT05979818·6 enrolled

Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer

Unknown status·SSun Yat-sen University·Phase 2·NCT04213170·60 enrolled

A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.

Unknown status·XXin-Hua Xu·Phase 2·NCT03863483·70 enrolled

Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT04728724·100 enrolled

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

Recruiting·JJinghui Wang·Phase 2·NCT06421298·30 enrolled

Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06620822·296 enrolled

Lung Cancer9 trials

First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial

Unknown status·QQianfoshan Hospital·Phase 3·NCT05648071·60 enrolled

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT04672356·19 enrolled

IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT05118334·30 enrolled

Show 6 more trials

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Unknown status·GGuangdong Association of Clinical Trials·Phase 2·NCT04252365·20 enrolled

Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer

Unknown status·TThe First Affiliated Hospital of Xiamen University·Phase 1/2·NCT04840758·39 enrolled

Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

Active, not recruiting· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT05116462·506 enrolled

Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer

Recruiting·SSichuan University·Phase 2·NCT06121505·114 enrolled

A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

Recruiting·JJinzhou Medical University·N/A·NCT06512207·80 enrolled

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

Recruiting·SSichuan University·Phase 1·NCT06431685·10 enrolled

Sintilimab8 trials

SinTilimab After Radiation (STAR Study)

Completed·PPeking Union Medical College Hospital·Phase 2·NCT04167657·14 enrolled

Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)

Unknown status·FFudan University·Phase 2·NCT05835245·30 enrolled

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

Completed·HHenan Cancer Hospital·Phase 2·NCT04055792·42 enrolled

Show 5 more trials

Sintilimab Plus NCT or NCRT Versus NCRT for ESCC

Not yet recruiting·SSichuan Cancer Hospital and Research Institute·Phase 3·NCT05244798·420 enrolled

Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL

Completed·HHuiqiang Huang·Phase 1/2·NCT03820596·40 enrolled

SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·N/A·NCT07474103·49 enrolled

Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL

Unknown status·SSun Yat-sen University·Phase 2·NCT04831710·83 enrolled

Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL

Unknown status·QQian Wenbin·Phase 2·NCT04659434·51 enrolled

77 more indications

Colorectal Cancer7 trials

Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）

Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT07007767·32 enrolled

Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis

Recruiting·FFudan University·Phase 2·NCT05057052·25 enrolled

ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

Recruiting·—·Phase 2·NCT06543836·68 enrolled

Show 4 more trials

Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer

Unknown status·PPeking Union Medical College Hospital··NCT04771715·100 enrolled

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

Recruiting·SSun Yat-sen University·Phase 3·NCT05236972·323 enrolled

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Recruiting·CChipscreen Biosciences, Ltd.·Phase 3·NCT06497985·430 enrolled

Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer

Recruiting·YYugui Lian·Phase 2·NCT06698757·96 enrolled

Esophageal Squamous Cell Carcinoma6 trials

Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection

Unknown status·FFujian Medical University Union Hospital·Phase 3·NCT06161909·400 enrolled

Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma

Recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT06413342·191 enrolled

Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma

Recruiting·HHenan Cancer Hospital·Phase 3·NCT05495152·219 enrolled

Show 3 more trials

Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma

Unknown status·SSichuan Cancer Hospital and Research Institute·Phase 2·NCT04602013·53 enrolled

A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)

Recruiting·SShanghai Chest Hospital·Phase 2·NCT06709417·52 enrolled

A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma

Not yet recruiting·FFudan University·Phase 2·NCT06152978·182 enrolled

Locally-advanced Rectal Cancer5 trials

Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer

Not yet recruiting·CChinese Academy of Medical Sciences·Phase 2/3·NCT05484024·588 enrolled

Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT04304209·195 enrolled

Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

Recruiting·—·Phase 2·NCT07040098·228 enrolled

Show 2 more trials

Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer

Active, not recruiting·TThe First Hospital of Jilin University·Phase 1·NCT04906044·46 enrolled

Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer

Recruiting·YYanhong Deng·Phase 2·NCT05450029·51 enrolled

Lymphoma5 trials

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Not yet recruiting·XXiuhua Sun·Phase 4·NCT06761911·100 enrolled

Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma

Unknown status·—·Phase 2·NCT04231370·20 enrolled

A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy

Unknown status· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT04044222·240 enrolled

Show 2 more trials

Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma

Completed·SSun Yat-sen University·Phase 2·NCT03936452·55 enrolled

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Unknown status·—·Phase 2·NCT04279379·20 enrolled

Nasopharyngeal Carcinoma5 trials

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 2·NCT05201859·150 enrolled

Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 3·NCT03700476·425 enrolled

PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 2·NCT03619824·40 enrolled

Show 2 more trials

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

Not yet recruiting·SSun Yat-sen University·Phase 3·NCT06900218·664 enrolled

Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma

Not yet recruiting·FFirst Affiliated Hospital of Guangxi Medical University·Phase 2·NCT06680115·150 enrolled

Cervical Cancer5 trials

Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer

Unknown status·BBuhai Wang·Phase 2·NCT04096911·20 enrolled

Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

Not yet recruiting·—·Phase 2·NCT07088731·180 enrolled

A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 2·NCT04590599·205 enrolled

Show 2 more trials

Adjuvant Chemotherapy and Anti-PD-1 Antibody in Patients With Stage IIIC2-IVB Cervical Cancer

Unknown status·TTaizhou Hospital·Phase 2·NCT04918628·50 enrolled

A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer

Unknown status·TThe Affiliated Hospital of Xuzhou Medical University·Phase 2·NCT05105672·20 enrolled

Metastatic Colorectal Cancer5 trials

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Active, not recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT05171660·446 enrolled

The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer

Unknown status·FFudan University·Phase 2·NCT04535024·60 enrolled

Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer

Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT06347198·30 enrolled

Show 2 more trials

Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Recruiting·DDai, Guanghai·Phase 2·NCT06685276·46 enrolled

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer

Recruiting·FFudan University·Phase 2·NCT06841159·116 enrolled

Adenocarcinoma4 trials

Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT04140318·60 enrolled

Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma

Recruiting·SSun Yat-sen University·Phase 2·NCT05170503·37 enrolled

Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Unknown status·SSichuan University·Phase 2·NCT04263870·36 enrolled

Show 1 more trial

Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT05625737·29 enrolled

Metastasis4 trials

Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis

Unknown status·SSun Yat-sen University·Phase 2·NCT04769908·40 enrolled

Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC

Withdrawn·SSun Yat-sen University·Phase 2·NCT04682249

Systemic Chemotherapy Plus PD-1 for Metastasis ICC

Withdrawn·SSun Yat-sen University·Phase 2·NCT04398927

Show 1 more trial

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT03802240·492 enrolled

Chemotherapy3 trials

Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC

Recruiting·FFudan University·Phase 1/2·NCT06494943·27 enrolled

PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT06788171·35 enrolled

Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC

Not yet recruiting·YYang Hong·Phase 2·NCT07309952·28 enrolled

Neoadjuvant Therapy3 trials

The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC

Active, not recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT04877821·31 enrolled

Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT05429463·250 enrolled

TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University·Phase 2/3·NCT05250843·90 enrolled

Bevacizumab3 trials

Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC

Unknown status·FFudan University·Phase 1/2·NCT04843943·30 enrolled

Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients

Active, not recruiting·SSun Yat-sen University·Phase 1/2·NCT04940546·36 enrolled

Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC

Unknown status·FFudan University·Phase 2·NCT05386524·41 enrolled

Advanced NSCLC3 trials

SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC

Unknown status·FFudan University·Phase 2·NCT04106180·63 enrolled

Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT03874000·43 enrolled

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT04672369·42 enrolled

Intrahepatic Cholangiocarcinoma2 trials

Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05251662·90 enrolled

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Completed·FFudan University·Phase 2·NCT05010668·28 enrolled

Biliary Tract Cancer2 trials

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）

Unknown status·FFudan University·Phase 2·NCT05781074·25 enrolled

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Unknown status· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1/2·NCT05653180·20 enrolled

Radiotherapy2 trials

Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

Recruiting·—·Phase 3·NCT07186621·286 enrolled

Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC

Unknown status·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT05292417·71 enrolled

Soft Tissue Sarcoma2 trials

The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma

Recruiting·FFudan University·Phase 1/2·NCT05839275·52 enrolled

The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma

Unknown status·FFudan University·Phase 2·NCT04356872·45 enrolled

Squamous Cell Carcinoma2 trials

Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05098119·43 enrolled

A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma

Unknown status·XXin-Hua Xu·Phase 2·NCT05749042·70 enrolled

Chemoradiotherapy2 trials

Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT04189094·140 enrolled

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Recruiting·SSun Yat-sen University·Phase 3·NCT05357846·422 enrolled

First-line Treatment2 trials

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT04720716·344 enrolled

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

Not yet recruiting· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 2·NCT05280626·100 enrolled

Treatment2 trials

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

Not yet recruiting·PPeking University Shenzhen Hospital·Phase 2·NCT06692491·200 enrolled

CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC

Not yet recruiting·FFudan University·Phase 2·NCT06652412·124 enrolled

Pancreatic Cancer2 trials

Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer

Recruiting·ZZhejiang University·Phase 1/2·NCT06572813·63 enrolled

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT05481476·32 enrolled

Gastroesophageal Junction Adenocarcinoma2 trials

A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma

Recruiting·FFudan University·Phase 2·NCT07492615·276 enrolled

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

Not yet recruiting·FFudan University·Phase 2·NCT06447636·20 enrolled

Anti-PD-1 Antibody2 trials

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

Unknown status·—·Phase 2·NCT05461235·1 enrolled

Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC

Unknown status·ZZhejiang University·Phase 2·NCT04174781·61 enrolled

Unresectable2 trials

cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria

Completed·FFudan University·Phase 2·NCT04842565·20 enrolled

HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05029973·30 enrolled

Advanced Solid Tumors2 trials

First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT03758001·38 enrolled

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Active, not recruiting·FFujian Haixi Pharmaceuticals Co., Ltd.·Phase 1/2·NCT06220318·155 enrolled

Newly Diagnosed1 trial

Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL

Unknown status·SSun Yat-sen University·Phase 2·NCT04994210·30 enrolled

Surufatinib1 trial

Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)

Recruiting·PPeking University·Phase 2·NCT05165407·30 enrolled

Neoadjuvant Chemotherapy1 trial

Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC

Not yet recruiting·SShanghai Chest Hospital·Phase 2·NCT06688656·30 enrolled

Resistance1 trial

IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT04945421·30 enrolled

Cutaneous T-cell lymphoma1 trial

Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT04296786·52 enrolled

Renal Cell Cancer1 trial

A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer

Unknown status·TTianjin Medical University Second Hospital·Phase 2·NCT04958473·40 enrolled

Cholangiocarcinoma1 trial

PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.

Unknown status·HHenan Cancer Hospital·Phase 2·NCT05207735·73 enrolled

Epstein Barr Virus1 trial

EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)

Unknown status·SSun Yat-sen University·Phase 2·NCT04072107·110 enrolled

Stereotactic Body Radiotherapy1 trial

Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular

Not yet recruiting·LLei ZHAO·Phase 2·NCT07352007·110 enrolled

Liver Transplant1 trial

IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation

Unknown status·RRenJi Hospital·N/A·NCT05339581·78 enrolled

Glioblastoma1 trial

The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma

Recruiting·FFifth Affiliated Hospital, Sun Yat-Sen University·Phase 2·NCT06220552·20 enrolled

Colorectal Carcinoma1 trial

Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Unknown status·SSun Yat-sen University·Phase 2·NCT04724239·48 enrolled

Combination Therapy1 trial

Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients

Recruiting·—·N/A·NCT06457477·50 enrolled

Clinical Trial1 trial

Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial

Recruiting·SSun Yat-sen University·Phase 2·NCT06031285·43 enrolled

Cancer of Unknown Primary1 trial

Sintilimab in Cancer of Unknown Primary

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT05024968·10 enrolled

Efficacy and Safety1 trial

A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors

Not yet recruiting·TTongji Hospital·Phase 2·NCT07053150·80 enrolled

Undifferentiated Pleomorphic Sarcoma1 trial

Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT05017103·6 enrolled

Angiosarcoma1 trial

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT05026736·6 enrolled

Phase II Clinical Study1 trial

Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical Study

Unknown status·SShanghai Cancer Hospital, China·Phase 2·NCT04513301·70 enrolled

Neoadjuvant Immunotherapy1 trial

Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC

Active, not recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT05244213·35 enrolled

Head and Neck Tumors1 trial

A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06240689·104 enrolled

Esophageal Cancer1 trial

Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer

Recruiting·SSichuan University·Phase 2·NCT06403878·68 enrolled

Colon Adenocarcinoma1 trial

Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma

Recruiting·—·Phase 2·NCT07468630·106 enrolled

Endometrial Cancer1 trial

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

Recruiting·HHutchmed·Phase 3·NCT06584032·412 enrolled

Small Cell Lung Cancer1 trial

A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT05026593·60 enrolled

Thyroid Cancer1 trial

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

Not yet recruiting·FFujian Medical University·Phase 4·NCT07010393·335 enrolled

Hypofractionated Radiotherapy1 trial

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Recruiting·WWest China Hospital·Phase 1/2·NCT04636008·20 enrolled

Concurrent Chemoradiotherapy1 trial

Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06341595·40 enrolled

First Line Therapy1 trial

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT03629925·357 enrolled

Premalignant Lesion1 trial

Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization

Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT04065737·29 enrolled

Advanced or Metastatic Solid Tumour1 trial

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Recruiting·IImmVirx Pty Ltd·Phase 1·NCT05427487·70 enrolled

Renal Cell Carcinoma1 trial

Sintilimab in FH-deficient Renal Cell Carcinoma

Unknown status·WWest China Hospital·Phase 2·NCT04146831·37 enrolled

Gastric Adenocarcinoma1 trial

A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT05594381·90 enrolled

Meningioma1 trial

Exploratory Study of PD-1 Neoadjuvant Treatment of Recurrent Meningioma

Unknown status·—·N/A·NCT04728568·15 enrolled

Patients With Advanced Solid Tumors1 trial

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT03545971·53 enrolled

Liver Resection1 trial

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

Not yet recruiting·WWan-Guang Zhang·N/A·NCT07077798·234 enrolled

Drug Resistance1 trial

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Unknown status·FFirst Hospital of Shijiazhuang City·Phase 2·NCT03765775·20 enrolled

Ovarian Clear Cell Carcinoma1 trial

Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma

Completed·TTongji Hospital·Phase 2·NCT04735861·38 enrolled

Induction Chemotherapy1 trial

Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

Unknown status·SSun Yat-sen University·Phase 2·NCT05008666·37 enrolled

Mucosal Melanoma1 trial

Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery

Recruiting·TThe First Hospital of Jilin University·Phase 2·NCT07400302·220 enrolled

T Cell1 trial

The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.

Unknown status·XXin-Hua Xu·Phase 2·NCT06029829·60 enrolled

Neuroblastoma1 trial

Study on Sintilimab in Stage IV High Risk Neuroblastoma

Unknown status·SShanghai Children's Medical Center·Phase 1·NCT04412408·10 enrolled

Borderline Resectable1 trial

Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC

Recruiting·LLei ZHAO·Phase 2·NCT06904014·40 enrolled

Breast Cancer1 trial

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

Not yet recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT06308939·81 enrolled

Adjuvant Therapy1 trial

A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC

Recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT06190639·31 enrolled

Advanced or Metastatic NSCLC1 trial

A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC

Unknown status·—·Phase 2·NCT04612673·33 enrolled

Completed·SSichuan University·Phase 1·NCT03812549·29 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC)

Unknown status·—·Phase 2·NCT05136768·50 enrolled

Neuroendocrine Neoplasm1 trial

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT05113355·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 294 trial records for sintilimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — sintilimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for sintilimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Innovent Biologics (Suzhou) Co. Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Programmed Cell Death Protein 1 Antagonist[2]
Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Innovent Biologics (Suzhou) Co. Ltd.